| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695475 | Gynecologic Oncology | 2017 | 8 Pages |
Abstract
MELK inhibition by OTSSP167 may thus present a strategy to treat patients with aggressive, progressive, and recurrent ovarian cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Reto S. Kohler, Henriette Kettelhack, Alexandra M. Knipprath-Mészaros, André Fedier, Andreas Schoetzau, Francis Jacob, Viola Heinzelmann-Schwarz,